4.4 Review

ITK Inhibitors in Inflammation and Immune-Mediated Disorders

期刊

CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 9, 期 8, 页码 690-703

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156802609789044443

关键词

-

资金

  1. NIH [AI51626, AI065566, AI073955]
  2. PA Department of Health
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065566, R01AI051626, R01AI073955, R56AI073955, R56AI065566] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and Fc epsilon R-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLC gamma, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据